Bacteriophages: what role may they play in life after spinal cord injury?

Spinal Cord - Tập 59 Số 9 - Trang 967-970 - 2021
Lorenz Leitner1, Shawna McCallin1, Thomas M. Kessler1
1Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland

Tóm tắt

AbstractBacterial infections are the leading cause of death in people with a spinal cord injury (SCI). Bacteriophages (phages) are viruses that solely infect and kill bacteria. The idea of using phages to treat bacterial infections, i.e., phage therapy, is very promising and potentially allows a more specific and personalized treatment of bacterial infections than antibiotics. While multi-drug resistant infections affect individuals from the general population, alternative therapeutic options are especially warranted in high-risk populations, such as individuals with SCI. However, more clinical data must be collected before phage therapy can be implemented in clinical practice, with numerous possible, subsequent applications.

Từ khóa


Tài liệu tham khảo

Bickenbach J, Bodine C, Brown D, Anthony Burns A, Campbell, Cardenas D, et al. International Perspectives on Spinal Cord Injury WHO: Geneva, Switzerland. 2013. WHO Library Cataloguing-in-Publication Data. 2013.

New PW, Jackson T. The costs and adverse events associated with hospitalization of patients with spinal cord injury in Victoria, Australia. Spine (Philos Pa 1976). 2010;35:796–802.

Waites KB, Canupp KC, Chen Y, DeVivo MJ, Moser SA. Bacteremia after spinal cord injury in initial versus subsequent hospitalizations. J Spinal Cord Med. 2001;24:96–100.

Savic G, DeVivo MJ, Frankel HL, Jamous MA, Soni BM, Charlifue S. Causes of death after traumatic spinal cord injury-a 70-year British study. Spinal Cord. 2017;55:891–7.

Leitner L, Kessler TM, Klumpp J. Bacteriophages: a panacea in neuro-urology? Eur Urol Focus. 2020;6:518–21.

Salmond GP, Fineran PC. A century of the phage: past, present and future. Nat Rev Microbiol. 2015;13:777–86.

Sybesma W, Zbinden R, Chanishvili N, Kutateladze M, Chkhotua A, Ujmajuridze A, et al. Bacteriophages as potential treatment for urinary tract infections. Front Microbiol. 2016;7:465.

Leitner L, Ujmajuridze A, Chanishvili N, Goderdzishvili M, Chkonia I, Rigvava S, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21:427–36.

Clarke AL, De Soir S, Jones JD. The safety and efficacy of phage therapy for bone and joint infections: a systematic review. Antibiotics. 2020;9:795.

Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care. 2017;21:129.

Wu LP, Ahmadvand D, Su J, Hall A, Tan X, Farhangrazi ZS, et al. Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. Nat Commun. 2019;10:4635.

Thông tin
Thông tin xuất bản

Spinal Cord

Tập 59 Số 9

967-970

Thông tin tác giả